ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

humanized bispecific antibody neutralizing both sclerostin AND DICKKOPF-1 (AGA-2115)

Its studies are mostly in Osteogenesis Imperfecta, led by 2 companies.

Drug pageHumanized bispecific antibody neutralizing both sclerostin AND DICKKOPF-1 (AGA-2115): every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jul 1, 20253 company-led studies, 2 open or runningNext primary completion: Nov 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Angitiaits history only21 open or runningphase 2since Jul 1, 2025Oct 11, 2023Nov 2027phase 2 · NCT07062588
Angitia Biopharmaceuticals Guangzhouits history only11 open or runningphase 2since Apr 23, 2026Apr 23, 2026Apr 2028phase 2 · NCT07557446

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 11, 2023First study: phase 1 study in Osteogenesis ImperfectaNew to AngitiaAngitia · NCT06086613 · 72 enrolled · United States
  2. Jul 1, 2025Phase 2 study in Osteogenesis ImperfectaAngitia · NCT07062588 · 80 planned · United States, Argentina, Australia and more
  3. Apr 23, 2026Angitia Biopharmaceuticals Guangzhou’s first study: phase 2 study in Osteogenesis ImperfectaNew to Angitia Biopharmaceuticals GuangzhouAngitia Biopharmaceuticals Guangzhou · NCT07557446 · 48 planned · China

Ahead

  1. Nov 2027Primary completion: phase 2 study in Osteogenesis ImperfectaAngitia · NCT07062588
  2. Apr 2028Primary completion: phase 2 study in Osteogenesis ImperfectaAngitia Biopharmaceuticals Guangzhou · NCT07557446

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07557446Osteogenesis Imperfecta · China2RecruitingAngitia Biopharmaceuticals GuangzhouApr 202848
NCT07062588Osteogenesis Imperfecta · United States, Argentina, Australia and more2RecruitingAngitiaNov 202780
NCT06086613Osteogenesis Imperfecta · United States1CompletedAngitiaOct 17, 202472

How it is read

Names in the registry

  • “AGA2115”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.